Business
Immunic to Participate in Scientific and Investor Conferences in June
NEW YORK, May 30, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small
About this update from Immunic, Inc.
[{"type":"text","content":"NEW YORK, May 30, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in June:\nMay 31-June 3: Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023. Robert J. Fox, MD, Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio, will present data from the open-label extension part of Immunic's phase 2 EMPhASIS trial of vidofludimus calcium (IMU-838) in relapsing-remitting multiple sclerosis at this conference in Aurora, Colorado. The poster presentation will be accessible on the \"Events and Presentations\" section of Immunic's website at: https://ir.imux.com/events-and-presentations.Poster Title: Assessment of Long-Term Safety and Tolerability of Vidofludimus Calcium in Patients with Relapsing Remitting Multiple Sclerosis in the Open-Label Extension Period of the Phase 2 Trial (EMPhASIS)Abstract ID: 8958Poster ID: DMT51Date: Thursday, June 1, 2023Time: 5:15 - 7:15 pm MT (7:15 - 9:15 pm ET)Location: Aurora Hall 1-3June 5-8: BIO International Convention. Members of Immunic's management and business development teams will attend this conference in Boston and participate in partnering activities. To schedule a meeting, please use the BIO International Convention partnering portal.About Immunic, Inc.\nImmunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), currently in phase 3 clinical trials for the treatment of multiple sclerosis and which has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and moderate-to-severe ulcerative colitis, selectively inhibits activated immune cells and shows combined anti-inflammatory, anti-viral and neuroprotective effects. IMU-856 is targeted to restore intestinal barrier function and regenerate bowel epithelium, which would be applicable in numerous gastrointestinal diseases, such as celiac disease, where it ...